Home

Cathflo administration pdf

Cathflo®: Non-stopcock method Page 2 of 2 10. Again assess catheter patency by attempting to aspirate blood. 11. If catheter patency has been restored, aspirate 4-5 ml of blood to remove Cathflo® and the residual clot. Proceed to step #13. 12. If catheter patency is not restored after one dose of Cathflo®, a second dose may be instilled Cathflo® ®Activase (alteplase) Dosing and Administration Cathflo 2 mg is the standard of care for treatment of thrombotically occluded catheters Please see Indication and Important Safety Information on reverse side. Please see full Prescribing Information below for additional Important Safety Information. Highest Level of Evidence i Cathflo ® Activase (alteplase) in Pediatrics Dosing and Administration Cathflo is the only FDA-approved treatment of thrombotically occluded pediatric catheters Patient weight Cathflo dose <30 kg (66 lb) 110% of the internal lumen volume of CVAD, not to exceed 2 mg in 2 mL 30 kg (66 lb) 2 mg in 2 mL 30 minutes 120 minutes 30 minutes 120 minute

Allow the Cathflo® solution to slowly fill the lumen (This may take up to 20 minutes to fill the lumen). When full, clamp the catheter. 10. After 30 minutes of dwell time, open the catheter clamp and assess catheter patency by attempting to aspirate blood. 11. If catheter patency has been restored, aspirate 4-5 ml of blood to remove Cathflo. Cathflo ® Activase (alteplase) in Pediatrics Dosing and Administration Cathflo is the only FDA-approved treatment of thrombotically occluded pediatric catheters Patient weight Cathflo dose <30 kg (66 lb) 110% of the internal lumen volume of CVAD, not to exceed 2 mg in 2 m 7-01-009 ADMINISTRATION OF CATHFLO ACTIVASE Page 2of REVISED: 11/2016 8. Turn the stopcock off to the Cathflo Activase filled syringe. This will open the stopcock to the empty syringe. 9. Pull back on the empty syringe plunger to approximately the 8 ml mark on the syringe and while maintaining negative pressure, turn the stopcock off to the. Review these general guidelines for administering Cathflo 8. Cathflo Administration. After WASHING hands and applying gloves 8: 1. After reconstitution using 2.2 mL sterile water for injection and aseptic technique, INSPECT solution for foreign matter and discoloration. 2. INSTILL the appropriate dose of Cathflo into the occluded catheter using.

Cathflo Activase [Alteplase] 2 Cathflo Activase 3 [Alteplase] 4 Powder for reconstitution for use in central venous access 5 devices 6 DESCRIPTION 7 Cathflo Activase [Alteplase] is a tissue plasminogen activator (t-PA) 8 produced by recombinant DNA technology. It is a sterile, purified 9 glycoprotein of 527 amino acids Alteplase for the treatment of central venous catheter occlusion in children: results of a prospective, open-label, single-arm study (the Cathflo Activase Pediatric Study). J Vasc Interv Radiol . 2006;17(11, pt 1):1745-1751 1. 2mg/2ml cathflo activase - reconstitute per manufacturers instructions 2. instillas a bolus using push pull technique per policy 60.2.15 3. check for blood return every 30 min x 4 4. when blood return obtained - aspirate 5 to 10cc and flush device with two 10 nss flushes. 1. have pharmacy mix 2 mg/2ml cathflo per lumen in: d5w 50cc nss 50cc 2

Alteplase (Cathflo®) Administration for Occluded Peritoneal Dialysis Catheter 1 BC Provincial Renal Agency • BCRenalAgency.ca November 2018. 3.0 Criteria for Use • Documented difficulty draining and or filling in the absence of kinks, tubing pressure, closed clamps, constipation. Cathflo® is a sterile, white to pale yellow, lyophilized powder for intracatheter administration (instillation) following reconstitution with Sterile Water for Injection, USP. INDICATIONS AND CLINICAL USE Cathflo® (alteplase, recombinant) is indicated for the restoration of function to central venous access devices. CONTRAINDICATION Cathflo Activase (Alteplase) is indicated for the restoration of function to central venous access devices (CVADs) as assessed by the ability to withdraw blood. Important Safety Information Cathflo Activase should not be administered to patients with known hypersensitivity to Alteplase or any component of the formulation • 20cc NS after blood product administration • Heparin 100 units/cc 2.5cc final flush in absence of continuous infusion and daily when line not in use . Sterile Dressing Change • Change dressing 24 hours post insertion • Every 7 days • Hibiclens followed by Chlorapre

Using Cathflo Activase in patients with infected catheters may release a localized infection into the systemic circulation. As with all catheterization procedures, care should be used to maintain aseptic technique. Hypersensitivity, including urticaria, angioedema and anaphylaxis, has been reported in association with use of Cathflo Activase Instructions for Administration (additions to current full Prescribing Information in bold+italics) Preparation of Solution . Reconstitute Cathflo Activase to a final concentration of 1 mg/mL IV alteplase administration decision making. I. A. 3. The use of telemedicine/ telestroke resources and systems should be supported by healthcare institutions, governments, payers, and vendors as one method to ensure adequate 24/7 coverage and care of acute stroke patients in a variety of settings. I

Cathflo® Activase® (alteplase) Administratio

administration whenever solution and container permit. Activase may be administered as reconstituted at 1 mg/mL or further diluted immediately before administration in an equal volume of 0.9% Sodium Chloride Injection, USP, or 5% Dextros reconstitution and administration of Cathflo Activase receive a copy of this letter, take inventory of which vials of Cathflo Activase are available for use, and specifically review the instructions for use. CAT/121214/0011 Genentech encourages the reporting of adverse events expeditiously. To report adverse events, product qualit Inspect the product prior to administration for foreign matter and discoloration. Withdraw 2 mL (2 mg) of solution from the reconstituted vial. Instill the appropriate dose of Cathflo Activase (see DOSAGE AND ADMINISTRATION) into the occluded catheter. After 30 minutes of dwell time, assess catheter function by attempting to aspirate blood administration whenever solution and container permit. Activase may be administered as reconstituted at 1 mg/mL or further diluted immediately before administration in an equal volume of 0.9% Sodium Chloride Injection, USP, or 5% Dextrose Injection, USP, to yield a concentration of 0.5 mg/mL, using either polyvinyl chloride bags or glass vials catheter patency is achieved after administration of Cathflo™ activase 2mg/ 2ml in 75% of central catheters after a dwell of up to 120 minutes. Additionally, after two doses of Cathflo™ activase 2mg/ 2mL, restoration of patency was achieved in 88% of central venous catheters with thrombotic occlusions. For patients with thrombotic occlusions o

Cathflo® Activase® (alteplase) Dosage & Administratio

Single-Use Vial Lytic Thrombolytic - Cathflo® Activase

  1. istration of Actilyse 5 Actilyse Cathflo is intended for intra-catheter instillation into dysfunctional central venous access devices, including those used for haemodialysis. 3.3 Procedure for ad
  2. istration of Alteplase (Cathflo) for Restoration of Patency I.D. #1049 In Peripherally Inserted Central Catheters (PICCs) Page 3 of 8 3.5.4 Don gloves. 3.5.5 Reconstitute Alteplase. Note: Alteplase will be supplied as a 2mg vial in powder form. 3.5.5.1 Inject 2.2 ml of sterile water into via
  3. istration Center for Drug Evaluation and Research Office of Prescription Drug Promotion 5901-B Ammendale Road Beltsville, MD 20705-126
  4. istration of Alteplase (Cathflo) with a completely occluded central line (stopcock method) Date:_____ Certifier Signature_____ Please place in the competency binder on your unit or with your annual review documentation sheets. Title: Competency checklist for Alteplase (Cathflo) ad
  5. istration. AFTER CARE: 1. Document in patient record: a. Measures taken to flush/aspirate line b. Communication with physician about occlusion B. ALTEPLASE/TPA ADMINISTRATION EQUIPMENT: Cathflo™ Activase (alteplase, TPA) 10 mL syringes (2) 3-way stopcoc

Dear Pharmacist Letter Cathflo (alteplase

Dornase Alfa - ACTIVE LEARNING TEMPLATE Medication STUDENT

Cathflo Activase Dosage Guide - Drugs

Dilution and reconstitution: Alteplase is a sterile, white to pale yellow lyophilized powder and should be reconstituted imme-diately before use. Administration: Reconstitute alteplase to a final concentration of 1 mg/ml. Preparation of solution 01. Withdraw 2.2 ml of sterile water for in-jection, USP. Diluent is not included When Cathflo Activase is administered for restoration of function to central venous access devices according to the instructions in DOSAGE AND ADMINISTRATION, circulating plasma levels of Alteplase are not expected to reach pharmacologic concentrations. If a 2 mg dose o The administration of alteplase is appropriate only for patients suffering ischaemic stroke if the onset is within the preceding 4.5 hours in select cases. The clinical guideline outlines the full eligibility criteria for application of alteplase. The guideline applies to acute stroke units/services, emergency departments (ED) the alteplase solution, and do not add other medications for administration to reconstituted alteplase. Dosing (Show first Dosing slide) The recommended dose of alteplase for treating acute ischemic stroke is 0.9 mg per kg. Alteplase is administered first as a bolus over one minute, followed by an infusion of the remaining dose over 60 minutes Cathflo Activase (Alteplase) for injection is a sterile, white to pale yellow, lyophilized powder for intracatheter instillation for restoration of function to central venous access devices following reconstitution with Sterile Water for Injection, USP. Each vial of Cathflo Activase contains 2.2 mg of Alteplase (which includes a 10% overfill.

tPA Mixing and Administration GENERIC NAME Alteplase TRADE NAME Activase APPLICABLE UNIT Emergency Department ACTION Tissue plasminogen activator (tPA) for thrombolysis INDICATION Treatment of acute ischemic stroke Critical Elements Usual Dosage Range and Route 0.9 mg/kg to a maximum of 90 m M. (2001). The use of alteplase to restore patency of central venous lines in pediatric patients: A cohort study. The Journal of Pediatrics,139(1),152-156. Gilarde, J. A., Chung, A. M., Vidal, R., & Falkos, S. (2006). Efficacy and economic evaluation of a volume-based Cathflo Activase protocol versus a fixed-dos Note: After successful administration of alteplase, heparin infusion should be introduced until warfarin achieves therapeutic INR (aortic: 3.0-4.0; mitral: 3.5-4.5) (Bonow, 2008). The 2012 ACCP guidelines for antithrombotic therapy make no recommendation regarding INR range after prosthetic valve thrombosis Alteplase (rt-PA-Activase®) dosage administration FULL DOSE: 0.9 mg/kg Administer 10% as a bolus over one minute and the remaining 90% over 60 minutes by continuous infusion. Alteplase concentration = 1 mg/mL (Calculations rounded to the nearest tenth) Pt weight (kg) Pt weight (lbs) Total dose (mL) Discard Quantity Bolus dose (mL) Infusion. INTERDISCIPLINARY CLINCAL Policy . This is a CONTROLLED document for internal use only. Any documents appearing in paper form are not controlled and should be checked against the electronic version prior to use

Cathflo Activase (alteplase) dose, indications, adverse

  1. ogen activator (t‑PA) produced by recombinant DNA technology. It is a sterile, purified glycoprotein of 527 a
  2. NIH Stroke Scale & Tips for tPA Ahren Dosch, M.S., RN Stroke Coordinator Essentia Health -Fargo Stroke & Neurovascular Cente
  3. istration of intravenous thrombolytic agents (recombinant tissue plas
  4. istration after reconstitution with sterilised Water for Injections. ACTILYSE 10 mg Box containing 1 vial of ACTILYSE 10 mg alteplase (corresponding to 5,800,000 IU) in up to 466.6 mg dry powder, 1 vial of sterilised Water for Injections, 10 mL. ACTILYSE 20 mg

Find information on Alteplase (Activase, Cathflo Activase) in Davis's Drug Guide including dosage, side effects, interactions, nursing implications, mechanism of action, half life, administration, and more. Davis Drug Guide PDF b. AHA 2019 guidelines state IV Alteplase administration within 21 d of a GI bleeding event is not recommended. If patient has had a GI hemorrhage from unclear etiology which has required a blood transfusion in the last week, do not treat with IV Alteplase (Stroke. 2019;50:e344- e418). c e46 Background and Purpose—The purpose of these guidelines is to provide an up-to-date comprehensive set of recommendations for clinicians caring for adult patients with acute arterial ischemic stroke in a single document. The intended audience Dosing and Administration Interactive Downloadable PDF. Activase® (alteplase) Dosing Slide Rule. Activase® (alteplase) Administration Sticker. Video: Dosing and Administration With Activase® (alteplase) 100-mg vials. Video: Dosing and Administration With Activase® (alteplase) 50-mg vials

Cathflo Activase (Alteplase Powder for Reconstitution for

For concurrent administration of alteplase and dornase alfa, using separate syringes, dilute each dose in 50 mL of normal saline. Instill each dose into chest tube, one immediately after the other, followed by a 60 mL normal saline flush. Clamp drain; after 2-hour dwell time, release clamp (Majid 2016).. Before starting antiplatelet agents or anticoagulation, wait 24 hours after alteplase administration and confirm stroke is stable with no evidence of hemorrhage via a follow-up non-contrast CT (or MRI). The risk of administering antiplatelet or anticoagulant therapy within 24 hours after alteplase is uncertain (AHA/ASA [Powers 2019]; Filho 2020. IV Alteplase (tissue plasminogen activator , IV-tPA) Treatment of Ischemic Stroke . For consideration of eligibility within 0-4.5 hours of Time Last Known Well . INCLUSION CRITERIA - Patients who should receive IV alteplase Symptoms suggestive of ischemic stroke that are deemed to be disabling, regardless of improvement (Se Indication. Cathflo ® Activase ® (Alteplase) is indicated for the restoration of function to central venous access devices as assessed by the ability to withdraw blood.. Important Safety Information. Cathflo Activase should not be administered to patients with known hypersensitivity to Alteplase or any component of the formulation Dosing & Administration Information for t-PA in Acute Ischemic Stroke, HC.STK.101A Acute Stroke Practice Guideline for Inpatient Management of Ischemic Stroke and Transient Ischemic Attack (TIA), HC.STK.102.HD NEU: Stroke/Rule out stroke/TIA Admission Orders NEU: Stroke Post Thrombolytic Therapy Originator/author OHSU Stroke Advisory Committe

Activase Description. Activase is a tissue plasminogen activator produced by recombinant DNA technology. It is a sterile, purified glycoprotein of 527 amino acids. It is synthesized using the complementary DNA (cDNA) for natural human tissue-type plasminogen activator obtained from a human melanoma cell line Action Date Submission Supplement Categories or Approval Type Letters, Reviews, Labels, Patient Package Insert Note Url; 02/28/2018: SUPPL-5260: Labeling-Package Inser Administration (FDA) package insert, specifically for the only tissue-type plasminogen activator licensed for use in acute ischemic stroke, alteplase. We did not include international guidelines or other international governmental restrictions on the use of alteplase because it was beyond the scope of this document Indication. Activase (alteplase) is indicated for the treatment of acute ischemic stroke. Exclude intracranial hemorrhage as the primary cause of stroke signs and symptoms prior to initiation of treatment. Initiate treatment as soon as possible but within 3 hours after symptom onset. Activase is indicated for use in acute myocardial infarction. Alteplase (t-PA) is a thrombolytic medication, used to treat acute ischemic stroke, acute ST-elevation myocardial infarction (a type of heart attack), pulmonary embolism associated with low blood pressure, and blocked central venous catheter. It is given by injection into a vein or artery. Alteplase is the same as the normal human plasminogen activator and is synthesized via recombinant DNA.

If major bleeding suspected, STOP Alteplase Medication Guide for controlling BP in patients during/after IV Alteplase administration for Acute Ischemic Stroke If BP>180/105 and HR>60, give labetalol 10 mg IV x1 over 2 min; If no response after 10 minutes, may repeat x1. O Cathflo Activase preparation. Reconstitute 2 mg vial by adding 2.2 mL SWI (do not use bacteriostatic water for injection); yields final concentration of 1 mg/mL. Mix by gently swirling until completely dissolved; complete dissolution occurs within 3 minutes; do NOT shake. Use within 8 hr if stored at room temperature

Less than 65 kg: 1.25 mg/kg administered as 0.75 mg/kg IV in the first hour (with 6 to 10 mg of it given as an IV bolus over 1 to 2 minutes), followed by 0.25 mg/kg/hour during hours 2 and 3. Heparin is usually given during and following administration of alteplase Alteplase also increased the risk of fatal intracranial hemorrhage within seven days (2.7 versus 0.4 percent, OR 7.14, 95% CI 3.98-12.79, NNH 44); this risk was similar regardless of age, stroke severity, or treatment delay. Alteplase treatment had no significant effect on other early or late causes of death The concomitant administration of heparin and aspirin with and following infusions of Activase for the treatment of acute ischemic stroke during the first 24 hours after symptom onset has not been investigated. Because heparin, aspirin, or Activase may cause bleeding complications, carefully monitor for bleeding, especially at arterial puncture.

Competency checklist for Alteplase (Cathflo

Title: ADMINISTRATION SET INFORMATION SHEET Author: asherjl Created Date: 8/23/2017 4:36:07 P The interaction of Cathflo with other drugs has not been formally studied. Using other drugs affecting coagulation and/or platelet function at the same time as Cathflo has not been studied. PROPER USE OF THIS MEDICATION Cathflo (alteplase, recombinant) is for intracatheter administration (instillation into the dysfunctiona si Cathflo® se retrouvait dans la circulation générale. Si l'administration de Cathflo® entraîne une réaction anaphylactoïde, il convient d'amorcer un traitement approprié. Populations particulières Grossesse L'administration de Cathflo® à des femmes enceintes n'a fait l'objet d'aucune étude. Des étude Cathflo Activase Dosing and Administration Guide 5. Soylu, H., Brandao, L.R., & Lee, K. (2010). Efficiancy of local instillation of recombinant tissue plasminogen activator for restoring occluded central venous catheters in neonates. The Journal of Pediatrics, 156: 197-201 Chest tube location for Alteplase (t-PA) /Dornase Alfa (DNase) administration: _____ 1. Check one of the following: place chest tube at -20 cm suction _____cm suction 2. Obtain Alteplase (t-PA) 10mg in 30 ml saline and Dornase Alfa (DNase) 5 mg in 30 ml sterile water, each in a separate leur-lock syringe 3

DailyMed - CATHFLO ACTIVASE- alteplase injection, powder

administration of both 1 and 2 doses of alteplase, as well as the proportion of patients reoccluding at least once. A 2-tailed z test for 2 means was used to evaluate the data available for mean time to reocclusion as well as the mean number of occlu-sions per patient. The 2-tailed z test for 2 means was also used to evaluate the demographic ag 2 DOSAGE AND ADMINISTRATION . 2.1. Individualized Dosing 2.2. Recommended Target INR Ranges and Durations for Individual Indications 2.3. Initial and Maintenance Dosing 2.4. Monitoring to Achieve Optimal Anticoagulation 2.5. Missed Dose 2.6. Intravenous Route of Administration 2.7. Treatment During Dentistry and Surgery 2.8. Conversion From. However, waiting time for catheter exchange increased from 20.36 ± 14 days in part 1 to 38.42 ± 28 days in part 2 (P < 0.05). The alteplase algorithm did not significantly reduce alteplase use. This may be partially explained by repeated use of alteplase in part 2, due to longer waiting times for catheter exchange procedures (Alteplase) Administration . For CDT, prescriber to order alteplase using the approved PowerPlan. The vials should . NOT . be shaken or agitated during preparation. Pharmacy to compound bolus syringe and remaining dose of alteplase for ED and ICU at VCMC. SPH ED to . prepare doses for emergent need. Se

following tPA administration. • Controlled and individualized BP management may be best achieved with IV antihypertensive medications. • Rapid lowering of BP in ischemic stroke patients may cause hypo-perfusion and result in poor patient outcomes. • Hyperthermia in stroke patients may damage penumbra and increase brain damage Administration: 1. The product should be visually inspected prior to administration for particulate matter and discoloration. TNKase™ may be administered as reconstituted at 5 mg/mL. 2. Precipitation may occur when TNKase™ is administered in an IV line containing dextrose alteplase. Discussion and criteria used to determine administration of IV alteplase are documented by the provider. IV alteplase is located in the EC, 5ICU PYXIS. IV alteplase is weight based and may be given by the Physician or Rapid Response RN. Call Pharmacy at . 743-4047 . for IV alteplase support if needed. Continue neuro checks an CATHFLO PACKAGE INSERT PDF. admin October 13, 2020. PRODUCT MONOGRAPH. PR. Cathflo. ® alteplase, recombinant . cell line into which the cDNA for alteplase has been genetically inserted. Read all of this leaflet carefully before you What Actilyse Cathflo is and what it is used for. 2

CATHFLO PACKAGE INSERT PDF - PRODUCT MONOGRAPH. PR. Cathflo. ® alteplase, recombinant . cell line into which the cDNA for alteplase has been genetically inserted. Read all of thi • IV alteplase within 4.5 hours of stroke onset remains the standard of care for most ischemic stroke patients, providing the opportunity for more favorable outcomes. Patients eligible for IV alteplase should receive it, even if mechanical thrombectomy is being considered

INTERDISCIPLINARY CLINCAL Polic

Activase® (Alteplase) is a tissue plasminogen activator produced by recombinant DNA technology. It is a sterile, purified glycoprotein of 527 amino acids. It is synthesized using Activase is a sterile, white to off-white, lyophilized powder for intravenous administration after reconstitution with Sterile Water for Injection, USP Alteplase (Cathflo®) 2 mL (2mg/2mL) administered as per medical directive into the electronic MAR (eMAR) and document the administration of Alteplase with another Registered Nurse or Registered Practical Nurses as a co-signer. Consistent with the documentation standards of the College of Nurses Ontario, th Alteplase binds to fibrin in a thrombus and converts the entrapped plasminogen to plasmin, thereby initiating local fibrinolysis. Refer to Alteplase in the Dialysis: Chronic Dialysis Services section of the appropriate Part 2 manual for the use of alteplase in chronic dialysis. Indications Alteplase is indicated for tPA (alteplase) Administration: Pt. Actual Weight _____Kg tPA (alteplase) 0.9 mg/kg (maximum of 90 mg) Total Dose _____ mg Bolus 10% of total dose given via IV infusion over 1 minute mg Infuse remaining 90% IV over the next 60 minutes mg Continue normal saline infusion at same rate until tPA clears tubing.

(110 or 150 mg twice a day); and the administration of idarucizumab prior to treatment with tPA. The exclusion criterion was the a final diagnosis of a stroke mimic. 2.2 Search Strategy The literature review was performed via a comprehensive search on MEDLINE, SCOPUS, and Web of Science databases up to 12 June, 2017. We used the followin alteplase. Discussion and criteria used to determine administration of IV alteplase are documented by the provider. Neurology places order for IV alteplase in Sunrise. IV alteplase is weightbased and may be - given by the Stroke neurology physician, ED RN or Rapid Response RN. Call Pharmacy at 743-4047 for support if needed

Cathflo Activase (Genentech, Inc

an otherwise eligible adult patient with a disabling AIS. In a recent trial, a lower dose of IV alteplase (0.6 mg/kg) was not shown to be equivalent to standard-dose IV alteplase for the reduction of death and disability at 90 days. 143. Main elements of post-thrombolysis care are listed on Table 7. See Table XXXIV in online Data Supplement 1 . 2013;44(3)870-947. While recognizing that the alteplase package insert was updated in February 2015, our general practice is to follow the recommendations in the AHA guidelines. *Treatment with IV tPA between 3 and 4.5 hours has not been approved by the FDA and is an off-label use for the treatment of acute ischemic stroke Title: GUIDELINES FOR TRANSFER OF PATIENTS ON IV ALTEPLASE Author: Patterson, Michele Subject: v1_Final; 08/2016 Created Date: 12/11/2017 12:29:57 P Reconstitute alteplase 20mg vial with 20mL water for injection. This can be retained for 24 hours at 2-8ºc and can be used for 2 doses. For a single dose, 10mg should be withdrawn and further diluted with 30mL sodium chloride 0.9%. Instil diluted alteplase first into the chest drain, clamp the drain for 1 hour and then unclam

VHA Directive 1155(1), Treatment of Acute Ischemic Strok

associated with the administration of Actilyse Cathflo can be caused by hypersensitivity tothe active substance alteplase, gentamicin (a trace residue from the manufacturing process), or toany of the excipients.,orThethestopper of the glass vial with Actilyse Cathflo powder whichcontains natura Sample pre-hospital stroke protocol (PDF) 5/18/2018 Sample EMS post IV alteplase transfer protocol (PDF) 11/2019 Transitions of Care. Stroke Patient Post-Discharge Follow-up and Data Collection Guide (PDF) 10/1/2020 Transitions of Care for Stroke Patients (PDF) 5/18/2018 Stroke Patient Transitions of Care Toolkit (PDF) 2/20/2019 Example: PDSA Worksheet for Testing Change (PDF The median time from onset to intravenous alteplase start was 165 minutes (interquartile range, 130-203), with 82% treated within 3 hours from onset and 17% between 3 and 4.5 hours. The median door-to-alteplase treatment time was 38 minutes (interquartile range, 26-55) View alteplase (Activase, Cathflo Activase).pdf from VNRS B85lv at Bakersfield College. ACTIVE LEARNING TEMPLATE: Medication STUDENT NAME_ alteplase (Activase, Cathflo Activase) MEDICATION_ REVIEW needle puncture sites, wounds) Medication Administration • Administer via IV infusion. • Give thrombolytic agents within 3 hr of the onset of. Thrombolytic (alteplase - tPA) Orders for Pulmonary Embolism (PE) Page 1 of 2 . 1. Inclusion: Massive PE

Alteplase (Activase, Cathflo Activase) Davis's Drug Guid

Ingelheim, Alteplase; 10% in bolus, 90% in perfusion >40 minutes) at different doses (0.9, 5, and 10 mg/kg, IV) and at different times after stroke onset (from 20 minutes to 4 hours) alteplase: haemorrhage (intracranial and gastrointestinal), recurrent ischaemia or angina, hypotension, heart failure, pulmonary oedema and reperfusion arrhythmias. For full details of adverse reactions and contraindications, see the summary of product characteristics. 2.3 The cost of alteplase is £135 per 10-mg pack, £180 per 20-mg pack and. CDT calls for direct intra-catheter drug delivery of low-dose alteplase and low-dose UFH, with an aPTT that should not exceed 1.5 x baselines to minimize the risk of bleeding in the setting of concomitant alteplase administration. However, given the diagnosis of HITT, argatroban was to be substituted in place of UFH 9 Clark WM, et al. Recombinant tissue-type plasminogen activator (Alteplase) for ischemic stroke 3 to 5 hours after symptom onset. The ATLANTIS Study: a randomized controlled trial. Alteplase Thrombolysis for Acute Noninterventional Therapy in Ischemic Stroke. JAMA 282(21):2019-26. 1999